All issues
Volume 64, Issue 3
Displaying 1-7 of 7 articles from this issue
- |<
- <
- 1
- >
- >|
-
Tohru MIZUSHIMA2015 Volume 64 Issue 3 Pages 241-253
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSThe number of drugs reaching the marketplace each year is decreasing, mainly because of the unexpected adverse effects of potential drugs being revealed at advanced stages of clinical trials. To circumvent this, we have proposed a new strategy for drug discovery and development, which focuses on the use of medicines that have already been approved for use by humans (drug re-positioning). In this strategy, compounds with clinically beneficial pharmacological activity are screened from a library of medicines already in clinical use to be developed for new indications. The advantage of this strategy is that there is a decreased risk of unexpected adverse effects in humans because the safety aspects of these drugs have already been well characterized in humans.View full abstractDownload PDF (2268K) -
Masashi SHIIBA, Katsuhiro UZAWA, Atsushi KASAMATSU, Yosuke ENDO-SAKAMO ...2015 Volume 64 Issue 3 Pages 254-261
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSIn order to understand the mechanism of chemo-resistance and radio-resistance in cancer treatment, micro-array analyses using several combinations of sensitive cells and resistant cells revealed candidate genes involved in the resistance. Furthermore, one gene with cancer-specific suppressed expression was detected by two-dimensional electrophoresis and time-of-flight mass (TOF MS) spectrometer resolution using normal cells and cancer cells in the oral epithelium, and its suppressive role in tumor metastasis was confirmed by the relationship between the gene expression status and the lymph-node metastasis and genetic function analyses. These genes were focused on as targeting genes in anticancer treatment.
In order to develop medicines for enhancing chemo-sensitivity and radio-sensitivity and to suppress metastasis of cancer cells, the drug repositioning method, which involves identifying and developing new uses for existing drugs, was used and several candidate drugs for clinical medicine were found. Finally, several drugs were narrowed down as possible clinical medicines by in vitro and in vivo functional analyses.View full abstractDownload PDF (1364K)
ORIGINAL ARTICLE
-
Akihiro KITA, Masashi SHIIBA, Dai NAKASHIMA, Morihiro HIGO, Atsushi KA ...2015 Volume 64 Issue 3 Pages 262-268
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSSurgery is the major approach for oral malignancies, however, other non-surgical treatments have been chosen in some cases for various reasons. The present study examined the clinical characteristics of non-surgical approaches for oral malignancies. From January 2000 to December 2012, 445 cases of primary oral squamous cell carcinoma were treated in our department and 69 (15.5%) patients underwent non-surgical treatment. Non-surgical approaches were chosen based on clinical factors such as excessive tumor progression, patient's will, advanced age, poor general condition, and views of family members. As non-surgical treatments, selective intra-arterial concurrent chemoradiotherapy, concurrent chemoradiotherapy, radiotherapy, chemotherapy, and palliative treatment were performed in 34 cases (49.3%), 15 cases (21.7%), 12 cases (17.4%), 6 cases (8.6%), and 2 cases (3.0%), respectively. The results revealed a 5-year overall survival rate of 28.3% in the non-surgical treatment group and 85.9% in the surgical treatment group. Median duration of survival was 25.8 months in the non-surgical treatment group. Six cases were treated by stereotactic radiotherapy using a cyberknife, and in those cases, complete response (CR) rate, CR/partial response (PR) rate and CR/PR/stable disease (SD) rate were 16.6%, 50.0% and 100%, respectively. The present data suggest that surgery should be the first choice in case of operation, and that selective intra-arterial concurrent chemoradiotherapy or stereotactic radiotherapy using a cyberknife has advantages for local management of oral squamous cell carcinoma.View full abstractDownload PDF (497K)
CASE REPORTS
-
Kouji OHTA, Masaaki TAKECHI, Hideo SHIGEISHI, Toshiya OKUMURA, Mutsumi ...2015 Volume 64 Issue 3 Pages 269-275
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSOdontogenic myxofibroma is a rare benign odontogenic tumor, but cases of local invasion are found exclusively in the jaw. Therefore, reconstruction of the jaw bone may be required after extensive surgical resection. We report a case of dental implant treatment and mandibular reconstruction using a titanium mesh tray and iliac particulate cancellous bone and marrow (PCBM) following mandibular resection for a large odontogenic myxofibroma. A 36-year-old female consulted an oral surgeon of another hospital for gingival swelling, and was referred to our hospital. An elastic-hard mass measuring about 26×20mm was located in the left molar region at initial examination. Thereafter, CT imaging revealed a large mass including an expansile, osteolytic lesion extending from the molar lesion to the mandibular ramus. The findings of a histopathological examination of an incisional biopsy specimen led to a diagnosis of odontogenic myxofibroma. Prior to surgery, a three-dimensional skull model was fabricated from CT data, then titanium mesh was bent and cut to form a tray simulating the original shape of the mandible based on the model. Under general anesthesia, we performed resection of the mandible and reconstruction using PCBM and the titanium mesh tray. Microscopically, the tumor consisted of odontogenic fibrous connective tissue involved with myxoid matrix, with some parts similar to a fibroma, which confirmed our final diagnosis of odontogenic myxofibroma. Three dental implants were inserted in the molar region at 10 months after surgery and two more were inserted at 12 months, thus forming a definitive prosthesis. Six years after surgery, no recurrence or implant failure were noted. We consider that this method is useful for implant treatment following extensive resection of the mandible, and may improve the patient's quality of life.View full abstractDownload PDF (966K) -
Yuki YONEMURA, Masayuki IMAI, Mai SHINNO, Masatoshi UDAGAWA, Satoshi Y ...2015 Volume 64 Issue 3 Pages 276-282
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSWe report the case of a 62-year-old man with angioedema induced by an angiotensin-converting enzyme inhibitor (ACE inhibitor) and an angiotensin II receptor blocker (ARB) who required tracheal intubation management. The patient had received an ACE inhibitor, an ARB and a Ca antagonist to treat hypertension. In June 2010, he visited our facility for emergency consultation at noon, with a chief complaint of swelling of the floor of the mouth and tongue which had occurred in the morning.
Endoscopy revealed laryngeal edema. As the respiratory symptoms rapidly exacerbated, orotracheal intubation was performed and the patient was admitted to the ICU. On the same day, the administration of dexamethasone and tranexamic acid was started. Therapy with the ACE inhibitor and ARB was discontinued, switching to a Ca antagonist only. Disappearance of swelling of the mouth floor and tongue was confirmed 3 days after admission, allowing extubation. The patient was discharged on day 9 after admission, and there has been no evidence of recurrence of the angioedema in the 38 months since ACE inhibitor and ARB were discontinued.View full abstractDownload PDF (817K)
-
2015 Volume 64 Issue 3 Pages 283-289
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSDownload PDF (829K) -
2015 Volume 64 Issue 3 Pages 290-304
Published: 2015
Released on J-STAGE: October 03, 2015
JOURNAL RESTRICTED ACCESSDownload PDF (1033K)
- |<
- <
- 1
- >
- >|